Postoperative ileus is a temporary slowdown or complete halt of bowel movement that commonly occurs after colorectal cancer surgery. It affects roughly 10 to 20% of patients who undergo these operations.
This condition causes abdominal bloating, pain, nausea, vomiting, and a delay in passing gas or stool. Beyond discomfort, it significantly extends how long patients must stay in the hospital, increasing both medical costs and the risk of further complications.
In the United States alone, the healthcare costs tied to postoperative ileus exceed 1.4 billion dollars annually. Given how often colorectal cancer surgery is performed - it is one of the most common cancer surgeries worldwide - finding ways to prevent or shorten this complication is a major clinical priority.
The causes of postoperative ileus are complex and involve the body's inflammatory response to surgery, disruption of the nervous system that controls the gut, pain medications, and changes in electrolyte balance - all of which interfere with normal bowel function.
Immunonutrition refers to nutritional supplements designed specifically to support and strengthen the immune system, not merely to provide calories and basic nutrients.
The key ingredients in immunonutrition formulas include glutamine (a conditionally essential amino acid), arginine (which supports wound healing and immune function), and omega-3 polyunsaturated fatty acids (such as fish oil, which reduce inflammation).
These nutrients work through different pathways: glutamine feeds the cells lining the intestine and helps maintain the gut barrier; arginine boosts the production of immune cells and reduces harmful inflammatory molecules; and omega-3 fatty acids shift the body's inflammatory balance toward healing and recovery.
Immunonutrition has been used in gastrointestinal cancer surgery for years to reduce infections and improve immune response, but whether it specifically helps the gut recover its normal movement after surgery has been less clear - which is why this meta-analysis was conducted.
The researchers conducted a systematic review and meta-analysis, which means they searched multiple medical databases to find every available randomized controlled trial (RCT) that tested immunonutrition in colorectal cancer patients. RCTs are considered the strongest type of evidence in medicine.
After extensive searching through databases including PubMed, Embase, and the Cochrane Library, the team identified 28 eligible trials involving 2,367 patients. These studies were conducted across many countries including China, South Korea, Italy, Japan, and Spain, and were published between 2002 and 2025.
The primary outcomes the researchers focused on were: time to first passing of gas (a key sign that bowel function is returning), time to first bowel movement, and the incidence of postoperative ileus itself. Secondary outcomes included hospital length of stay, overall complications, and abdominal bloating.
To combine results from different studies, the team calculated mean differences for time-related outcomes and risk ratios for complication rates, using statistical methods to account for variation between studies. They also checked for publication bias, which occurs when studies with favorable results are more likely to be published than those with neutral ones.
The pooled analysis showed that immunonutrition significantly shortened the time to first flatus (first passing of gas after surgery) by an average of about half a day (0.56 days). This was based on data from 20 trials and was statistically highly significant.
Similarly, immunonutrition shortened the time to first bowel movement by approximately 0.51 days. While this finding came from only 6 trials, it was still statistically significant, demonstrating that the gut recovers its motility faster when patients receive these targeted nutrients.
These improvements may seem small in absolute terms, but in the context of surgery recovery they are clinically meaningful. Earlier bowel function means patients can start eating sooner, feel more comfortable, and face fewer complications - each of which contributes to faster overall recovery and discharge from hospital.
Importantly, despite substantial statistical variation (heterogeneity) between the included trials - which was expected given the different immunonutrition formulas and timing used - the direction of benefit was consistent across studies.
Beyond bowel recovery, immunonutrition also reduced the length of hospital stay by an average of 1.47 days. This finding was drawn from 17 trials and was statistically significant, suggesting that the quicker recovery facilitated by immunonutrition translates into earlier discharge.
The incidence of overall postoperative complications was 36% lower in patients who received immunonutrition compared to those who did not (risk ratio 0.64). This was based on 21 trials and suggests that immunonutrition not only speeds recovery but helps prevent problems like infections and wound complications.
Immunonutrition also significantly reduced postoperative abdominal distension (bloating) - patients in the immunonutrition group were about 67% less likely to develop this symptom, based on 4 trials. This suggests a real reduction in one of the most uncomfortable aspects of post-surgery recovery.
The one finding that did not reach statistical significance was the direct incidence of clinically diagnosed postoperative ileus. This may partly reflect inconsistent definitions of ileus across different studies, which is an important limitation the authors acknowledge and call for future standardization.
Glutamine is the primary fuel source for cells lining the intestine. After surgery, the body's glutamine stores can become depleted due to the metabolic stress of the operation. Supplementing with glutamine helps maintain the structural integrity of the intestinal lining and keeps the gut immune system functioning, reducing the chance of bacteria leaking into the bloodstream.
Arginine acts as a building block for nitric oxide, which improves blood flow through the small blood vessels supplying the intestine. Better circulation means the intestinal cells get more oxygen and nutrients they need to resume their normal function. Arginine also suppresses inflammatory molecules like TNF-alpha and interleukin-6 that can disrupt bowel motility.
Omega-3 fatty acids from fish oil directly compete with pro-inflammatory molecules in the body's signaling pathways. By shifting the balance away from inflammation, they reduce the immune system's damaging response to surgical trauma. Studies have also shown omega-3s may positively affect the gut microbiome, which plays a role in regulating bowel movement.
Surgery activates the sympathetic nervous system (the body's stress response), which suppresses intestinal movement. The inflammatory cascade triggered by the operation releases molecules like interleukin-1 and interleukin-6 that further damage intestinal smooth muscle. By blunting these responses, immunonutrition helps the gut return to its normal rhythm sooner.
The 0.5-day reduction in bowel recovery and 1.5-day reduction in hospital stay may seem modest, but applied across tens of thousands of colorectal cancer surgeries performed annually, they represent a substantial collective reduction in healthcare burden and patient suffering.
For patients undergoing colorectal surgery, these findings suggest that asking your care team about perioperative immunonutrition may be worthwhile. The supplements can be given before surgery (preoperative), after surgery (postoperative), or during both periods (perioperative).
Shorter hospital stays also have implications for long-term cancer outcomes. Patients who recover faster are more likely to be able to start adjuvant chemotherapy or other follow-up treatments on schedule, which can influence survival.
The findings are particularly relevant in the context of Enhanced Recovery After Surgery (ERAS) protocols, which are modern perioperative care pathways designed to minimize surgical stress and speed recovery. Immunonutrition fits naturally within these protocols as one component of a comprehensive approach to improving outcomes after colorectal cancer surgery.
While the evidence is encouraging, the authors highlight several important limitations. Many of the included trials were small and conducted at a single center, which may limit how broadly the results can be applied. There was also significant variation between studies in the type of immunonutrition used, the timing of supplementation, and the dosage.
A major challenge is the lack of a universal definition of postoperative ileus. Without a standardized diagnostic criteria, it is difficult to directly compare results across studies or determine exactly how much immunonutrition reduces this specific complication.
Future research should focus on identifying the optimal immunonutrition formula and timing - for example, whether preoperative supplementation alone is sufficient, or whether continuing it after surgery provides additional benefit. Specific subgroups such as elderly patients, malnourished individuals, and those who received neoadjuvant chemotherapy or radiation before surgery warrant dedicated study.
The authors call for large-scale, multicenter randomized trials using standardized immunonutrition protocols and consistent definitions of outcomes to confirm these findings and establish clear clinical guidelines. Until then, immunonutrition should be considered a promising and generally safe adjunct to standard surgical care for colorectal cancer patients.